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Abstract
Introduction—Elevated levels of tissue factor positive (TF+) microparticles (MPs) are observed
in plasma from a variety of patients with an increased risk of thrombosis. We and others have
described the measurement of TF activity in MPs isolated from plasma. The aim of this study was
to investigate the effects of pre-analytical and analytical variables on TF activity of MPs isolated
from blood of healthy volunteers treated ex vivo with or without bacterial lipopolysaccharide.
Materials and Methods—We evaluated the following parameters: use of different
centrifugation speeds to isolate the MPs; comparison of TF activity of MPs isolated from platelet
poor plasma versus platelet free plasma; effect of freeze/thaw on MP TF activity; and comparison
of the MP TF activity assay with the measurement of TF protein by ELISA or flow cytometry.
Results—MPs prepared from platelet poor plasma by centrifugation at 20,000 × g or 100,000 × g
for 15 minutes had similar levels of TF activity. However, significantly less TF activity was found
in MPs isolated from platelet free plasma compared with platelet poor plasma. Interestingly,
freeze/thawing of the plasma showed donor to donor variation in MP TF activity, with a moderate
increase in some individuals.
Conclusion—TF+ MPs can be quantitatively isolated from platelet poor or platelet free plasma
by centrifugation at 20,000 × g for 15 minutes. Measurement of MP TF activity in plasma can be
used to detect a prothrombotic state in patients with various diseases.
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Tissue factor (TF) is a transmembrane protein that is the primary initiator of the coagulation
cascade. TF is constitutively expressed on perivascular cells and epithelial cells and
activates the clotting cascade in the event of vascular injury [1–3]. Very low levels of TF are
also present in blood [4]. Recently, TF expression was found in a subset of resting
monocytes [5]. Importantly, TF expression is strongly induced on monocytes exposed to
bacterial lipopolysaccharide (LPS) [6, 7].
The majority of the low levels of TF present in plasma of healthy individuals is in the form
of microparticles (MPs) [8]. These are small vesicles of variable size (0.1–1μm) that are
released from many different cell types upon apoptosis or cellular activation and possess cell
surface markers that are characteristic of their parental cells [9]. An alternatively spliced
version of TF is also present in blood and is soluble due to the absence of a transmembrane
domain [10]. Exposure of anionic phospholipids, such as phosphatidylserine (PS), on the
surface of cells and MPs is associated with an increase in TF activity [11]. Increased levels
of circulating TF+ MPs have been found in various disease states, including cancer [12–14],
sickle cell disease [15], myocardial infarction [16], venous thromboembolism (VTE) [17],
endotoxemia and sepsis [18, 19]. However, at present there is no standard method for the
measurement of TF activity in plasma [8, 20, 21].
The aim of the current study was to evaluate pre-analytical and analytical variables that
affect levels of MP TF activity. We used blood from healthy volunteers treated ex vivo with
LPS to generate monocyte-derived TF+ MPs. We also compared levels of MP TF activity
with levels of TF protein measured using two commercial TF ELISAs and by flow
cytometry. Finally, we performed dilution linearity experiments to assess the lower limit of
detection of the MP TF activity assay.
Materials and Methods
Materials
Bacterial lipopolysaccharide (LPS) (E. coli serotype 0111:B4) and mouse IgG were
purchased from Sigma Aldrich (St. Louis, MO, USA). An inhibitory mouse anti-human TF
monoclonal antibody (HTF-1) was generously provided by Dr. Ronald Bach (VAMC,
Minneapolis, MN, USA). Human recombinant relipidated TF (Innovin) was obtained from
Dade Behring (Marburg, Germany). Human Factor VIIa and Factor X were obtained from
Enzyme Research (South Bend, IN, USA). The Factor Xa chromogenic substrate
Pefachrome (FXa 8595) was obtained from Centerchem, Inc (Norwalk, CT, USA). The
IMUBIND® TF ELISA and the fluorescein isothiocyanate (FITC) conjugated, murine
monoclonal antibody against human TF (Product no. 4507CJ) were obtained from American
Diagnostica (Stanford, CT, USA). The ZYMUTEST TF ELISA kit was kindly provided by
HYPHEN BioMed (France). FITC conjugated mouse IgG isotype control and
allophycocyanin (APC) conjugated annexin V were obtained from BD Pharmingen (San
Diego, CA, USA).
Blood collection and treatment
The subjects for this study were 14 healthy volunteers between the ages of 18–45. All
subjects were Caucasian, and male subjects represented 80% of the group. Not all donors
were used for every experiment. Samples were collected and processed in accordance with
the Office of Human Research Ethics at UNC-Chapel Hill, and informed consent was
obtained from all participating subjects. Blood was collected by venipuncture into
Vacutainer® tubes containing 0.129 M sodium citrate using a 21 gauge needle (Becton-
Dickinson, Plymouth, UK). The first 3 mL of blood was discarded to minimize
contamination from traumatic tissue injury. Control plasma was obtained by centrifugation
Lee et al. Page 2













of whole blood at the time of blood draw. Plasma containing elevated levels of TF+ MPs
was generated by treating whole blood with LPS (10 μg/ml) for 5 hours at 37°C with gentle
rocking. Plasma samples were aliquoted, snap frozen, and stored at −80°C for ≤ 1 month
before use.
Plasma preparation and isolation of MPs
Platelet poor plasma (PPP) was prepared from whole blood by centrifugation at 1,500 × g
for 15 minutes at room temperature. Platelet free plasma (PFP) was prepared from PPP with
an additional centrifugation at 13,000 × g for 2 minutes at 4°C. Plasma samples were either
analyzed fresh or snap frozen in liquid nitrogen and stored at −80°C. MPs were pelleted
from either PPP or PFP by centrifugation at either 20,000 × g or 100,000 × g for 15 minutes
at 4°C. 1 mL samples were spun in a fixed-angle, 45 degree rotor with 20 positions of 11
mm diameter each. For samples that were spun at 100,000 × g, an ultracentrifuge with a
fixed-angle rotor at 45 degrees was used (Optima™ TLX Ultracentrifuge, Beckman Coulter,
Brea, CA, USA).
MP TF activity assay
A two stage chromogenic assay for the measurement of MP TF activity has been described
[14].
MP TF assay sensitivity and intra-assay variation
The TF concentration of Innovin was determined using the IMUBIND® TF ELISA. An
overlay of Innovin standard curves from 14 independent experiments was created by
plotting observed values against the predicted value for each point. A regression line was
fitted to the curve using statistical software. Dilution linearity experiments with MPs were
also performed to determine the lower limit of the MP TF activity assay. PPP from LPS
treated blood of 3 donors was serially diluted by half to 1/128 the concentration of the
original sample before MPs were prepared and MP TF activity was measured. The observed
values, calculated from the standard curve, and the expected values, based on the dilution
factor, were plotted on a log-log scale against 1/dilution factor. The coefficient of variation
(CV) was determined by dividing the standard deviation by the mean for each sample group.
Flow cytometry
MPs were isolated as described above from PFP derived from LPS-treated (10 μg/mL, 5
hours) or untreated blood. In addition, we analyzed MPs from untreated and LPS-treated
THP-1 culture supernatant. Samples were analyzed fresh. MPs were stained in APOP buffer
(137 mM NaCl, 5 mM KCl, 1 mM MgCl2, 0.1% BSA ± 2.5 mM CaCl2) with an APC
conjugated annexin V (BD Pharmingen) and a FITC conjugated mouse monoclonal antibody
to human TF (American Diagnostica). Samples were analyzed on the Becton-Dickinson
LSR II (Plymouth, UK) with Flo Jo software. To ensure that an equal volume of each
sample was analyzed, flow runs were terminated at either 1000 fluorescent flow count beads
(Beckman Coulter) or after a 30 second time interval. Graph is expressed as the average fold
increase of TF+ annexin V+ double positive MP events of treated versus untreated samples,
in which untreated samples are standardized to a value of 1.
Measurement of TF by ELISA
Plasma levels of human TF protein were measured by IMUBIND® TF ELISA kit
(American Diagnostica) and ZYMUTEST TF ELISA kit (HYPHEN BioMed) according to
the manufacturer's instructions.
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For comparisons between multiple groups, a two-way ANOVA with Bonferroni post-test
analysis was performed using GraphPad Prism version 5.00 for Windows (GraphPad
Software, San Diego California USA). Unless otherwise noted, data are expressed as mean ±
standard deviation and statistical significance is defined by p < 0.05.
Results
Sensitivity and intra-assay variability of the MP TF activity assay
The MP TF activity assay uses a standard curve generated with different concentrations of
recombinant TF (Innovin, Dade Behring). We assessed the standard error and goodness of
fit of 8 points along the curve from 14 standard curves performed on different days. Though
error increased with higher concentrations of TF, we found that the standard error and
standard deviation from the mean was minimal (SEM ≤0.02, sd ≤0.08, Figure 1A). In order
to assess the sensitivity of the MP TF functional assay, we used PPP from LPS treated blood
of 3 donors, serially diluted to 1/128 of the original concentration. MPs were isolated and TF
activity measured. As shown in Figure 1 B–D, the actual value obtained deviated from the
value expected from the dilution factor at 0.52, 0.34, and 0.03 pg/mL for the 3 donors,
indicating that the sensitivity of the assay was ~0.50 pg/mL.
To evaluate the between run, intra-operator variability of the MP TF activity assay we
calculated the CV of LPS-stimulated samples from four independent studies, with 3–5
assays per study run on different days. The CV in each independent study ranged from 12–
25%.
Comparison of the MP TF activity and protein assays
We prepared plasma from unstimulated and LPS stimulated blood and measured levels of
MP TF activity and TF protein in the plasma using two commercial sandwich ELISAs. In
each assay, plasma from the same six donors was used. MPs were isolated by centrifugation
at 20,000 × g for 15 minutes. The mean level of MP TF activity for the unstimulated
samples was below the lower limit of detection of the assay (0.11 ± 0.07 pg/mL). All donors
exhibited a large increase in MP TF activity in blood treated with LPS compared with
unstimulated controls (Figure 2A). Consistent with the known variability in LPS response in
the population, we observed differences in the level of TF induction among the individual
donors [5]. Levels of MP TF activity in LPS treated blood from the different subjects ranged
from 2.0–14.4 pg/mL. In contrast to the MP TF activity assay, unstimulated plasma samples
had a high signal in the IMUBIND® TF ELISA (Figure 2B). The level of TF was modestly
increased by LPS treatment in plasma from 5 of 6 donors with the IMUBIND® TF ELISA
(1.4 ± 0.3 fold, Figure 2B) but was not increased using the ZYMUTEST TF ELISA (Figure
2C). Notably, there were large differences in basal levels of TF protein between the two
ELISAs with a high level in the IMUBIND® ELISA (263.9 ± 32.9 pg/mL) and a low level
in the ZYMUTEST ELISA (8.8 ± 1.9 pg/mL).
Next, the number of TF+ PS+ double positive MPs was analyzed by flow cytometry in a
subset of the same cohort of volunteers (n=5) and in THP-1 culture supernatant as a positive
control. Surprisingly, we found that numbers of TF+ MPs isolated from PFP were not
significantly increased compared with untreated samples. In contrast, significantly more TF+
PS+ events were observed in the cell supernatant of LPS stimulated cells compared with the
culture supernatant of untreated cells (***p<0.001, Figure 3).
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Pre-analytical variables affecting MP TF activity
Different centrifugation speeds have been reported for the preparation of plasma and the
isolation of MPs, with some studies using ultra high speed centrifugation, such as 100,000 ×
g, to pellet MPs [21]. We and others have used 20,000 × g for 15 minutes to isolate MPs [14,
22]. Therefore, we compared the amount of MP TF activity isolated from PPP using 20,000
and 100,000 × g. Pelleting MPs from PPP at these two centrifugal forces for 15 minutes
yielded similar amounts of MP TF activity from LPS treated blood (Figure 4A). Next, we
compared the amount of MP TF activity from either PPP or PFP derived from the same LPS
treated blood using a 20,000 × g, 15 minute spin. Levels of MP TF activity from PFP were
significantly lower (52% reduction) than those isolated from PPP (3.9 ± 2.4 vs. 2.2 ± 1.9 pg/
mL, Figure 4B).
Effect of freeze/thaw on MP TF activity
Cellular TF activity is significantly increased after cell lysis due to increased exposure of PS
[11]. We hypothesized that freeze/thaw of plasma would increase PS levels on the surface of
MPs and therefore increase TF activity. We compared TF activity of MPs isolated from
fresh plasma versus plasma that was snap frozen and thawed once. Variable results were
observed with the 5 donors, with PPP from 3 of 5 donors showing a modest increase in MP
TF activity (1.3–2.3 fold) after a freeze-thaw cycle (*p<0.05, **p<0.01, Figure 4C).
However, when the MP TF activities of the 5 donors were combined and the activity of the
fresh sample defined as 1, the MP TF activity of frozen PPP compared to fresh failed to
reach statistical significance (paired student's t-test, p=0.06, data not shown).
Discussion
In this study, we determined the effect of pre-analytical plasma preparation and storage on
MP TF activity. Currently, the lack of standardization of pre-analytical variables has
hindered researchers analyzing MPs [8, 20, 21, 23]. The most critical and discrepant
variables include methods of plasma preparation, MP isolation, and storage of samples. For
example, assay variability has been shown to be associated with different centrifugation
protocols [24, 25]. Ultra centrifugation of ≥100,000 × g for up to 60 minutes has been used
to isolate MPs [15]. However, this may contaminate the MPs with smaller exosomes. We
found no significant difference in TF activity of MP isolated from PPP using 100,000 × g or
20,000 × g indicating that the lower speed is sufficient to quantitatively recover TF+ MPs
from plasma.
Previous studies have examined the number of MPs isolated from PFP and PPP using
different centrifugation protocols. One study observed an 80% reduction in the number of
MPs by spinning PPP at 13,000 × g for 2 minutes [26]. Similarly, we found that MP TF
activity from PFP was reduced by 52% compared to the MP TF activity obtained from PPP.
Despite this reduction, the level of MP TF activity was still easily detected in PFP. Another
study found that plasma prepared using 2,000 × g for 10 minutes followed by 21,472 × g for
10 minutes had 10 fold less MPs than PPP (prepared by 1,550 × g for 20 minutes) [27].
Since our assay measures the procoagulant activity of TF that is affected by the availability
of PS, cryopreservation and storage of samples is a critical pre-analytical variable when
analyzing samples for MP TF activity. For instance, freezing of PPP results in platelet
fragmentation [28]. Another study found that the total number of MPs and TF+ MPs was
decreased by freeze-thaw [29]. There is also some discrepancy in the literature regarding PS
exposure on MPs. One study found a 20 fold increase in surface PS on MPs after freeze-
thawing by flow cytometry [26]. In contrast, another group did not observe a change in PS
exposure after freeze-thawing of MPs by flow cytometry (F. Dignat-George, pers. com.).
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This is consistent with Tesselaar and colleagues [12] who found no difference in MP TF
activity in fresh versus frozen and thawed samples. We found donor to donor variability in
MP TF activity of fresh PPP and PPP that had been snap frozen and thawed once, with 3 of
5 donors exhibiting an increase in activity. It is possible that some of this variability may be
due to differences in platelet contamination of the PPP. MP TF activity may be increased in
samples with higher levels of platelets due to PS exposure on the platelets. However, it
should be noted that the increase in TF activity in these 3 donors after freeze/thaw was
modest (1.3–2.3 fold), and no significant increase in TF activity was observed when data for
the 5 donors was combined. These results may explain some of the reported discrepancies in
the effect of freeze/thaw on PS exposure on MPs and MP TF activity.
We compared our MP TF activity assay with two different methods that measure TF protein.
We found the MP TF activity assay was able to detect much larger differences in LPS
stimulated versus unstimulated samples with low background activity in the unstimulated
samples. Only one of the two commercial TF ELISAs showed a modest increase in TF
protein levels after LPS stimulation but had a high basal level of TF protein (263.9 ± 32.9
pg/mL). One study raised concerns about the high levels of TF protein levels detected using
commercial TF ELISAs [30]. In a previous study, we found a much lower level of TF
protein (27 pg/ml) in healthy individuals using an “in-house” TF ELISA [14]. Using flow
cytometry, we found no statistical difference between levels of TF+ MP isolated from
unstimulated and LPS stimulated blood. In contrast, MPs isolated from LPS-treated THP-1
culture supernatant showed a significant increase in TF protein compared with MPs derived
from untreated THP-1 culture supernatant (***p<0.001). One explanation for these results is
that a large number of TF+ MPs released from activated monocytes in whole blood bind to
activated platelets and are removed by centrifugation and this significantly reduces their
number in the plasma. We have found in a time-course experiment with LPS treated whole
blood that levels of TF in monocytes precede the levels of TF in platelets [31], which is
consistent with transfer of monocyte-derived TF+ MPs to platelets. In addition, other studies
have shown that monocyte-derived TF+ MPs bind to platelets [32, 33]. These results also
suggest that the TF activity assay is more sensitive than flow cytometry in detecting TF+
MPs. However, TF+ MPs can be detected in the plasma of patients with different diseases
[8, 12, 15, 18, 25], indicating that our in vitro model is not optimal for looking at TF+ MPs
by flow.
The dilution linearity experiments indicate that MP TF activity below 0.5 pg/mL cannot be
accurately detected with this assay. Importantly, we have shown that plasma from cancer
patients have higher MP TF activities than 0.5 pg/mL, while plasma from healthy
individuals tend to have levels below this concentration [14, 34]. We observed a CV of 12–
25% using different samples and with 3 different operators. A previous study reported a CV
of <10% using a similar MP TF activity assay [27]. These variations are inherent in a
biological assay.
Standardization of the measurement of TF+ MPs in plasma is needed so that results from
different labs can be compared. TF+ MPs may be a useful biomarker for identifying patients
at risk for thrombosis. Further refinement of this and other assays is necessary for analysis
of levels of TF+ MP in clinical samples.
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Figure 1. MP TF assay sensitivity
A) Standard curve of relipidated, recombinant MP TF from MP TF assays (n=14). OD
values were back-calculated from the standard curve and plotted against the expected value
for each point. A regression line was fitted to the curve using statistical software, r2=0.97.
B–D) Dilution linearity plots from 3 donors, where x equals the point at which the diluted
sample deviates from the predicted curve. Black squares represent predicted values and
white circles represent observed values.
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Figure 2. MP TF activity and protein in samples prepared from blood with and without LPS
stimulation
Whole blood from 6 donors was either stimulated for 5 hours with LPS (10 μg/mL) or left
untreated. PPP from blood with or without LPS stimulation was analyzed for A) MP TF
activity and TF protein by B) IMUBIND® TF ELISA and C) ZYMUTEST TF ELISA.
Black bars represent MP isolation from LPS treated blood and white bars indicate MPs
isolated from untreated blood. Samples were run in triplicate, *p<0.05, ***p<0.001, two-
way ANOVA post-test.
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Figure 3. Flow cytometric analysis of TF+ PS+ MPs
MPs were isolated by centrifugation of PFP from either untreated or LPS-stimulated whole
blood from 5 donors or from centrifugation of untreated or LPS-stimulated THP-1 cell
supernatant (10μg/mL of LPS, 5 hours). The graph is expressed as the average fold increase
of TF+ annexin V+ double positive MP events of treated versus untreated samples, in which
untreated samples are standardized to a value of 1. Black bars represent MP isolation from
LPS treated blood or LPS treated THP-1 cells and white bars indicate MPs isolated from
untreated blood or unstimulated cells. Samples were run in triplicate, ***p<0.001 by two
way ANOVA post-test.
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Figure 4. Effect of pre-analytical variables on MP TF activity
A) MP TF activity of PPP from whole blood from 6 donors stimulated with LPS (10 μg/mL)
for 5 hours and then spun at either 20,000 × g or 100,000 × g for 15 minutes. B) MPs from 5
donors were isolated from PPP or PFP from LPS treated blood by centrifugation at 20,000 ×
g for 15 minutes. C) MP TF activity of PPP from LPS-stimulated blood was analyzed fresh
or after being snap frozen and thawed once. Samples were run in triplicate, *p<0.05,
**p<0.01, ***p<0.001 by two way ANOVA post-test.
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